Barclays
JBIO

Barclays’s Jade Biosciences JBIO Stock Holding History

Barclays’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$503K Sell
22,634
-2,026
-8% -$42.3K ﹤0.01% 3228
2026
Q1 		$346K Sell
24,660
-47,534
-66% -$688K ﹤0.01% 3388
2025
Q4 		$1.11M Buy
72,194
+26,427
+58% +$310K ﹤0.01% 3355
2025
Q3 		$395K Sell
45,767
-229,063
-83% -$1.87M ﹤0.01% 3950
2025
Q2 		$2.75M Buy
274,830
+274,413
+65,806% +$9.34M ﹤0.01% 2598
2025
Q1 		$36.7K Sell
417
-195
-32% -$17.1K ﹤0.01% 4681
2024
Q4 		$56.8K Buy
612
+70
+13% +$6.03K ﹤0.01% 4729
2024
Q3 		$39.7K Buy
542
+410
+311% +$26.4K ﹤0.01% 4795
2024
Q2 		$7.67K Sell
132
-93
-41% -$61.7K ﹤0.01% 4542
2024
Q1 		$233K Sell
225
-215
-49% -$164K ﹤0.01% 4039
2023
Q4 		$348K Buy
440
+330
+300% +$168K ﹤0.01% 4111
2023
Q3 		$52.2K Buy
110
+13
+13% +$7.04K ﹤0.01% 3849
2023
Q2 		$58.4K Sell
97
-38
-28% -$24.3K ﹤0.01% 3772
2023
Q1 		$95.2K Buy
135
+24
+22% +$19.9K ﹤0.01% 4210
2022
Q4 		$113K Buy
111
+100
+909% +$72.6K ﹤0.01% 4153
2022
Q3 		$6K Sell
11
-104
-90% -$69.4K ﹤0.01% 4448
2022
Q2 		$63K Sell
115
-50
-30% -$23.9K ﹤0.01% 3951
2022
Q1 		$105K Buy
+165
New +$64K ﹤0.01% 3756

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's JBIO Position: Q2 2026 in Review

Barclays reduced its Jade Biosciences (JBIO) stake by 8.2% in Q2 2026, selling an estimated $42.3K and leaving 22,634 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #3228.

Barclays first reported a position in JBIO in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.75M in Q2 2025. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Barclays held 22,634 shares of Jade Biosciences worth $503K as of Q2 2026.
  • Barclays sold 2,026 Jade Biosciences shares in Q2 2026, an estimated $42.3K.
  • Jade Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3228 holding.
  • Barclays first reported a position in Jade Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Jade Biosciences position peaked at $2.75M in Q2 2025.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.